2. Academic Validation
  3. Evaluation of a series of bicyclic CXCR2 antagonists

Evaluation of a series of bicyclic CXCR2 antagonists

  • Bioorg Med Chem Lett. 2008 Jan 15;18(2):798-803. doi: 10.1016/j.bmcl.2007.11.039.
Iain Walters 1,  Caroline Austin,  Rupert Austin,  Roger Bonnert,  Peter Cage,  Mark Christie,  Mark Ebden,  Stuart Gardiner,  Caroline Grahames,  Steven Hill,  Fraser Hunt,  Robert Jewell,  Shirley Lewis,  Iain Martin,  David Nicholls,  David Robinson
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom. iain.walters@astrazeneca.com
PMID: 18240390 DOI: 10.1016/j.bmcl.2007.11.039
Abstract

The CXCR2 SAR of a series of bicyclic antagonists such as the 2-aminothiazolo[4,5-d]pyrimidine 3b was investigated by systematic variation of the fused pyrimidine-based heterocyclic cores. Replacement of the aminothiazole ring with a 2-thiazolone alternative led to a series of thiazolo[4,5-d]pyrimidine-2(3H)-one antagonists with markedly improved biological and pharmacokinetic properties, which are suitable pharmacological tools to probe the in vivo effects of CXCR2 antagonism combined with the associated CCR2 activity.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z